Epirubicin hydrochloride [56390-09-1]
Référence T0125-500mg
Conditionnement : 500mg
Marque : TargetMol
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
Epirubicin hydrochloride
(Synonyms: Pharmorubicin, Epirubicin HCl, 4'-Epidoxorubicin hydrochloride, 4'-epidoxorubicin HCl) Copy Product Info
Epirubicin hydrochloride (Pharmorubicin) is an adriamycin derivative, a topoisomerase (Topo) inhibitor, and a Forkhead box protein p3 (Foxp3) inhibitor. Epirubicin hydrochloride has antitumor activity.
Cas No. 56390-09-1
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.79%
Color:Red
COA HPLC HNMR
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Epirubicin hydrochloride (Pharmorubicin) is an adriamycin derivative, a topoisomerase (Topo) inhibitor, and a Forkhead box protein p3 (Foxp3) inhibitor. Epirubicin hydrochloride has antitumor activity. |
| Targets & IC50 | Hepatoma G2 cells proliferation:1.6 μg/mL (24h), synthesis and function of DNA:62.7 μM (in rat glioblastoma cell lines), Topoisomerase II:12 μM |
| In vitro | METHODS: Neuroglioma cells U-87 and neuronal primary cultures were treated with Epirubicin hydrochloride (0.5-100 µM) for 48 h. Cell viability was measured by MTT assay. RESULTS: Epirubicin significantly reduced the viability of rat U-87 cells in a concentration-dependent manner, with an IC50 of 6.3 µM. In contrast to U-87 glioma cells, rat normal neuronal cells were resistant to Epirubicin. [1] METHODS: Human breast cancer cells MDA-MB-231 and SK-BR-3 were treated with Epirubicin hydrochloride (2-3 µM) for 48 h, and apoptosis was detected by Flow cytometry. RESULTS: Epirubicin significantly increased sub-G cells in G2/M block. [2] |
| In vivo | METHODS: To test the antitumor activity in vivo, Epirubicin hydrochloride (7 mg/kg) was administered intravenously three times at four-day intervals to BALB/c nu/nu nude mice bearing MDA-MB-231 xenografts. RESULTS: Epirubicin reduced tumor growth by half and resulted in a more than 10% weight loss. the IR value of Epirubicin at 7 mg/kg was 53.3%. [2] |
| Synonyms | Pharmorubicin, Epirubicin HCl, 4'-Epidoxorubicin hydrochloride, 4'-epidoxorubicin HCl |
| Cell Research | Hep G2 cells (500 cells/well, monolayer) are plated in a 96-well plate. The next day the cells are treated with Epirubicin in the medium. At the end of the incubation periods, 15% volume of MTT dye solution is added. After 1 hr of incubation at 37℃, an equal volume of solubilization/stop solution (dimethylsul-foxide) is added to each well for an additional 1 hr incubation. The absorbance of the reaction solution at 570 nm is recorded.(Only for Reference) |
| Molecular Weight | 579.98 |
| Formula | C27H30ClNO11 |
| Cas No. | 56390-09-1 |
| Smiles | Cl.COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO |
| Relative Density. | 1.61g/cm3 |
| Storage | Store at low temperature,Store under nitrogen Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 42.86 mg/mL (73.9 mM), Sonication is recommended.  Ethanol: 5.8 mg/mL (10 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 5% DMSO+95% Saline: 2.9 mg/mL (5 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||